Feb 21, 2025 · Lennox-Gastaut syndrome is a chronic, treatment-resistant form of epilepsy that typically starts before the age of 8 years. It is characterised by a distinct electroencephalogram pattern and ...

Dec 3, 2024 · Lennox-Gastaut syndrome is a severe form of childhood that causes frequent . Several types of seizures are usually present at the same time, including atonic or tonic seizures. These …

Jun 27, 2016 · GW Pharmaceuticals announced positive topline phase 3 results for its investigational cannabidiol product in patients with Lennox-Gastault syndrome.

Jan 25, 2018 · Epidiolex, a purified oral form of cannabidiol, significantly reduced drop seizure frequency in patients with highly drug-resistant Lennox-Gastaut syndrome and could be available later this year.

Apr 20, 2017 · Adding cannabidiol (CBD) to antiepileptic drug (AED) therapy significantly reduces the frequency of drop seizures in patients with Lennox-Gastaut syndrome (LGS), results of a phase 3 …

Feb 18, 2025 · Participants will receive Epidiolex, a concentrated formulation of CBD approved by the FDA in 2018 for the treatment of seizures associated with two rare forms of epilepsy: Lennox …

Apr 20, 2021 · Sirven emphasized that CBD is only indicated for three types of epilepsy: Dravet syndrome, Lennox-Gastaut syndrome, and drug-resistant epilepsy.

Feb 10, 2023 · Already approved for Dravet syndrome, fenfluramine's approval for seizure control in Lennox-Gastaut syndrome was supported by data from a global, phase 3 clinical trial.

Mar 29, 2022 · Already approved for Dravet syndrome, fenfluramine (Fintepla) for seizure control in LGS was supported by data from a global, randomized, placebo-controlled phase 3 clinical trial.

May 5, 2022 · Fenfluramine led to a significant reduction in drop seizures associated with Lennox-Gastaut syndrome when added to an existing anti-epileptic treatment regimen in the pivotal phase 3 …